Status:
UNKNOWN
Coagulation/Complement Activation and Cerebral Hypoperfusion in Relapsing-remitting Multiple Sclerosis
Lead Sponsor:
Regina Elena Cancer Institute
Collaborating Sponsors:
University of Roma La Sapienza
Icahn School of Medicine at Mount Sinai
Conditions:
Multiple Sclerosis
Relapse
Eligibility:
All Genders
18-60 years
Brief Summary
This is a multi-center, prospective, controlled study. MS patients (1° group: 30 patients in relapse; 2° group: 30 patients in remission) and age/sex-matched healthy controls (3° group: 30 subjects) w...
Eligibility Criteria
Inclusion
- patients diagnosed with relapsing-remitting multiple sclerosis, untreated or treated with only immunomodulatory therapy, in relapse o in remission
Exclusion
- pregnant, with any neoplastic, hematologic, thyroid, metabolic, thrombotic or autoimmune disease, drug or alcohol addicted, treated with immunosuppressive drugs, steroids o any medication interfering with coagulation.
Key Trial Info
Start Date :
September 7 2017
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 31 2020
Estimated Enrollment :
80 Patients enrolled
Trial Details
Trial ID
NCT04380220
Start Date
September 7 2017
End Date
December 31 2020
Last Update
May 21 2020
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Icahn School of Medicine at Mount Sinai
New York, New York, United States, 10029
2
IRCCS Regina Elena National Cancer Institute
Rome, Italy, 00144
3
University of Rome Sapienza
Rome, Italy, 00189